Observations of DIA 2023

The first Drug Information Association (DIA) Annual Conference that I attended was the one in 1997 in Montreal. If one could look back at each of them through time lapse photographs quite a story it would tell. In bullet format: 

  • The growth of the CRO industry through mergers and acquisitions
  • Scirex was the late night party sponsor
  • Fax and OMR/OCR data collection was a high-tech blip on the screen until – 
  • EDC appeared with much noise but took longer than necessary to be adopted due to the inherent risk-aversion in the industry
  • Global trials for phase III studies
  • Patient recruitment via advertising had great stories to tell of saving trials
  • Transperfect is the late night party sponsor
  • Randomization and Drug Management system advances led to the ability to do increasingly complex trials and save millions of dollars in reducing drug waste
  • ePRO proved that paper diary data wasn’t reliable
  • Patient recruitment adjusted to pay for results (randomized patients)
  • eTMF vendors increase
  • Risk-based monitoring software appears
  • Integration of multiple sources of data
  • CluePoints is the late night party sponsor
  • Forced by Covid-19 we learned how to conduct decentralized trials, remote monitoring visits, mobile sites, tele-visits
  • Figuring out how to get EHR/EMR data into clinical trial databases
  • Insurance claims data allowing for Real World Evidence trials
  • The importance of patient diversity in clinical trials
  • AI gives a peek at our new future incredibly shortening study start-up: scan of protocol creates informed consent, eCRFs & edit checks, site instructions in 30 minutes not 8 – 12 weeks

These advances promise a brighter future for the population with illnesses seeking to be healthy and maximize quality of life. 

I make a point of walking the entire exhibit hall every year. It allows me to sense the change in the needs of the industry, the new products, new services. I can also run into people who may have changed companies since our previous interactions. When I talk at the first time attendee orientation on Monday morning, I recommend everyone visit the exhibit hall and to be inquisitive – look at what the exhibitors are doing, ask questions, find opportunities to be helpful and/or build relationships and connections. 

The content presented at DIA is prepared, submitted and presented by industry members who voluntarily do so. I encourage fellow industry members to submit an abstract. Abstract submissions are due September 14. The topics of interest and the instructions for submitting an abstract can be found here: https://www.diaglobal.org/abstract/meeting-details?productID=13251490&productcode=24001CFA

As a speaker, you receive a significant discount on the conference registration. It’s also a good addition to your career experience and can help you in networking and being seen as a key industry expert. 

We hope to see you at DIA 2024 in San Diego.

 

May 2023 Networking Event Summary

May 17, 2023 

As our passion is to connect people and companies we know and respect to other people and companies we know and respect, we open the meeting asking everyone to put the link to their LinkedIn profile in the chat. This facilitates future communication and connections. 

Before we had our featured presenter begin, we shared industry info and upcoming events. A newish conference called: Clinical Research as a Care Option took place in Raleigh in mid-May. We mentioned that we’d be holding a networking event the night prior. It was stated that Joan Chambers would be attending. Joan recently joined Greater Gift as the CEO. Greater Gift’s mission is to increase awareness of clinical trials, especially among unrepresented communities, like women, ethnic minorities, individuals from diverse socio-economic and educational backgrounds. ds. 

At this point, we had 21 attendees and we turned over the meeting to Steve Galen, PhD with Validcare. The focus of the presentation was to talk about how not to run out of funding before you get a read on the success of your product. Validcare has the tools and technology to forward plan a trial, find potential bottlenecks and prepare for them. With so many eclinical tools available, the predictability of the cost of a trial is greatly improved. This disruptive change shakes up the traditional and archaic approach of CRO’s low-bidding a project only to begin issuing change orders shortly after the study starts.  Such an approach prevents the biotech from managing their financial spend. Steve is an experienced clinical research professional having worked at Merck, Covance, PRA, Syneos and Navitas.  

Reminder of these meetings’ guidelines: 

  • Think of this as an open house event – drop in when you can and leave when you need to; 
  • When we have a presenter we have them start when we have assembled a strong amount of respondents – usually 10-15 minutes after the start. 
  • Presenters’ topics are not sales pitches – the focus is on an aspect of clinical trials; where in the process their services are used and aspects of that step. 
  • The link to get the GLSA newsletter and notifications about future live and virtual events:  http://bit.ly/3UTb8hL
  • We ask everyone to put their LinkedIn link into the chat to facilitate connecting and future follow up. 
  • To read the April summary https://focmnetworking.com/networking/april-2023-networking-event-summary/

Attendees:
Steve Galen, PhD, Validcare & the evening presenter
Ira Snyder, Consultant
Holly Jochims, Adaptive Clinical Systems
Joan Chambers, Greater Gift
Brian Langin, Diligent Pharma
Mike O’Gorman; Life Science Marketplace
Kevin Boos; Aixial Group
Amy Lee, PharmD
Michael Young, biomedwoRx
Ali Hussein, Science 37
Viljena Trask, Syneos Health
Sumitra Sheeri, S-Clinical

GLSA Attendees:

Katie Barrett
Joe Buser
Chris Matheus
Denise McNerney
Hannah Lloyd
Timmina Williams
Charity Dube
Jordan Brown
Sally Haller
Ori Geshury
Liz Mirra